J&J scores an­oth­er PhI­II win for Er­lea­da as it con­tin­ues to build a block­buster fran­chise

Just un­der a year since J&J won ap­proval from the FDA to start mar­ket­ing Er­lea­da (apa­lu­tamide) for non-metasta­t­ic prostate can­cer, the phar­ma gi­ant has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.